Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $452.04, giving the company a market capitalization of 115.02B. It carries a P/E multiple of 31.43.
During the trading session on 2025-12-12, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $456.00 and a low of $442.68. At a current price of $452.04, the stock is +2.1% higher than the low and still -0.9% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 1.61M, versus its average volume of 1.38M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Vertex Pharmaceuticals (VRTX) has quietly outperformed the broader biotech space over the past year, despite a recent pullback. That mix of near term weakness a...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $530.00. TipRanks Cyber Monday Sale Cl...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene...
Analyst ratings
61%
of 36 ratingsMore VRTX News
In a report released on December 5, Salveen Richter from Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $604.00. TipRan...
If you are wondering whether Vertex Pharmaceuticals at around $455 a share is still a smart buy or if the best days are already priced in, you are not alone. T...
Vertex Pharmaceuticals (VRTX) announced data from multiple studies demonstrating the clinical benefits of CASGEVY in people ages 5 years and older living with s...
Key Points Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has ex...
(RTTNews) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the...